Literature DB >> 10703869

The angiotensin type 2 receptor: variations on an enigmatic theme.

T Unger1.   

Abstract

Since its discovery and molecular characterization, the angiotensin AT2.receptor has been enigmatic with respect to signalling pathways and function. Evidence now emerges that angiotensin II exerts actions through the AT2 receptor which are directly opposed to those mediated by the AT1 receptor. This can be exemplified e.g. by mutually antagonizing effects on cell growth. Upregulated by the endogenous agonist itself, as well as by several growth- and differentiating factors in development and tissue injury, the AT2 receptor appears to act as a modulator of complex biological programmes involved in embryonic development, cell differentiation, tissue protection and regeneration, as well as in programmed cell death. Research on the AT2 receptor has thus unveiled hitherto unknown functions of the renin-angiotensin system extending far beyond the classical role of this old hormonal system in cardiovascular control.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10703869     DOI: 10.1097/00004872-199917121-00001

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  19 in total

Review 1.  Angiotensin AT2 receptor ligands: do they have potential as future treatments for neurological disease?

Authors:  Philip Rosenstiel; Stefan Gallinat; Alexander Arlt; Thomas Unger; Jobst Sievers; Ralph Lucius
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 2.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

3.  Role of the angiotensin II receptor blocker valsartan in heart failure.

Authors:  R L Webb; M de Gasparo
Journal:  Exp Clin Cardiol       Date:  2001

Review 4.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

5.  Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [³H]dopamine and [³H]norepinephrine release.

Authors:  Vidya Narayanaswami; Sucharita S Somkuwar; David B Horton; Lisa A Cassis; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2013-07-04       Impact factor: 5.858

Review 6.  Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?

Authors:  Michael J Osgood; David G Harrison; Kevin W Sexton; Kyle M Hocking; Igor V Voskresensky; Padmini Komalavilas; Joyce Cheung-Flynn; Raul J Guzman; Colleen M Brophy
Journal:  Ann Vasc Surg       Date:  2012-03-22       Impact factor: 1.466

7.  Identification of membrane-bound variant of metalloendopeptidase neurolysin (EC 3.4.24.16) as the non-angiotensin type 1 (non-AT1), non-AT2 angiotensin binding site.

Authors:  Naomi J Wangler; Kira L Santos; Ines Schadock; Fred K Hagen; Emanuel Escher; Michael Bader; Robert C Speth; Vardan T Karamyan
Journal:  J Biol Chem       Date:  2011-10-28       Impact factor: 5.157

8.  Angiotensin type 2 receptors in the intermediolateral cell column of the spinal cord: negative regulation of sympathetic nerve activity and blood pressure.

Authors:  Jie Chao; Juan Gao; Karma-Jaya K Parbhu; Lie Gao
Journal:  Int J Cardiol       Date:  2013-07-18       Impact factor: 4.164

Review 9.  Development of fetal brain renin-angiotensin system and hypertension programmed in fetal origins.

Authors:  Caiping Mao; Lijun Shi; Feichao Xu; Lubo Zhang; Zhice Xu
Journal:  Prog Neurobiol       Date:  2009-01-24       Impact factor: 11.685

Review 10.  Impact of the AT(2) receptor agonist C21 on blood pressure and beyond.

Authors:  Sébastien Foulquier; U Muscha Steckelings; Thomas Unger
Journal:  Curr Hypertens Rep       Date:  2012-10       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.